Kestra Medical Technologies (KMTS) Cash & Equivalents (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Cash & Equivalents data on file, last reported at $262.2 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 10.36% year-over-year to $262.2 million in Q2 2026; TTM through Apr 2026 was $262.2 million, a 10.36% increase from a year earlier, with the FY2026 full-year figure at $262.2 million, up 10.36% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $262.2 million, down from $291.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for KMTS reached as high as $291.3 million in Q1 2026 and fell as low as $8.2 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $142.3 million across 3 years, with a median of $137.7 million in 2024.
• Across the five-year window, Cash & Equivalents surged 2780.29% in 2025 and climbed 10.36% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $76.9 million in 2024, then surged by 128.07% to $175.4 million in 2025, then jumped by 49.47% to $262.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $262.2 million in Q2 2026, $291.3 million in Q1 2026, and $175.4 million in Q4 2025.